- Home
- SWTX vs PTGX Comparison
SWTX vs PTGX Comparison
Compare SWTX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- PTGX
- Stock Information
- Founded
- SWTX 2017
- PTGX 2006
- Country
- SWTX United States
- PTGX United States
- Employees
- SWTX N/A
- PTGX N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SWTX Health Care
- PTGX Health Care
- Exchange
- SWTX Nasdaq
- PTGX Nasdaq
- Market Cap
- SWTX 2.8B
- PTGX 2.7B
- IPO Year
- SWTX 2019
- PTGX 2016
- Fundamental
- Price
- SWTX $34.63
- PTGX $36.82
- Analyst Decision
- SWTX Strong Buy
- PTGX Strong Buy
- Analyst Count
- SWTX 6
- PTGX 8
- Target Price
- SWTX $68.83
- PTGX $54.63
- AVG Volume (30 Days)
- SWTX 1.5M
- PTGX 660.4K
- Earning Date
- SWTX 02-25-2025
- PTGX 02-25-2025
- Dividend Yield
- SWTX N/A
- PTGX N/A
- EPS Growth
- SWTX N/A
- PTGX N/A
- EPS
- SWTX N/A
- PTGX 2.68
- Revenue
- SWTX $135,487,000.00
- PTGX $323,795,000.00
- Revenue This Year
- SWTX $3,413.86
- PTGX $441.08
- Revenue Next Year
- SWTX $88.52
- PTGX N/A
- P/E Ratio
- SWTX N/A
- PTGX $13.72
- Revenue Growth
- SWTX N/A
- PTGX 125.73
- 52 Week Low
- SWTX $28.21
- PTGX $23.89
- 52 Week High
- SWTX $53.92
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- SWTX 43.67
- PTGX 39.62
- Support Level
- SWTX $31.96
- PTGX $35.03
- Resistance Level
- SWTX $44.01
- PTGX $40.07
- Average True Range (ATR)
- SWTX 3.20
- PTGX 1.56
- MACD
- SWTX -0.47
- PTGX -0.04
- Stochastic Oscillator
- SWTX 19.53
- PTGX 34.89
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.